Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
CAMBRIDGE, MA—KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Chief Medical (TASE:BLWV) Officer Paul K. Audhya recently sold shares worth approximately $30,700, according to a recent SEC filing. The transaction, dated February 18, involved the sale of 3,125 shares at an average price of $9.8242 per share. The stock has shown strong momentum recently, gaining over 12% in the past week and 26% year-to-date, with the current trading price at $10.71.
The sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) and performance stock units (PSUs). This "sell to cover" transaction was not discretionary on Audhya’s part. According to InvestingPro data, KalVista maintains a strong liquidity position with a current ratio of 6.87, though the company’s overall financial health score remains weak.
In addition to the sale, Audhya also acquired a total of 6,447 shares of common stock through the exercise of RSUs on February 17, at no cost. Following these transactions, Audhya holds 100,334 shares of KalVista Pharmaceuticals directly. The company is scheduled to report its next earnings on March 12, with analysts maintaining a strong buy consensus and setting price targets between $18 and $39.
In other recent news, KalVista Pharmaceuticals Inc has been the focus of several significant developments. The company has received Orphan Drug Designation for its lead drug candidate, sebetralstat, from Japan’s Ministry of Health, Labour and Welfare. Alongside this, KalVista has submitted a New Drug Application in Japan, aiming to introduce the first oral on-demand treatment for hereditary angioedema (HAE) in the country. Moreover, TD Cowen initiated coverage of KalVista, assigning a Buy rating with a price target of $30.00, citing the potential for sebetralstat to exceed $750 million in peak sales. JMP Securities has also maintained a Market Outperform rating with a $19.00 price target, emphasizing the drug’s potential in the HAE market. Analysts from JMP Securities suggest that the HAE market, valued at around $900 million, is poised for growth with the introduction of sebetralstat. The company has also filed for regulatory review of sebetralstat with the U.S. FDA, with a decision expected by June 17, 2025. KalVista’s efforts in advancing HAE treatment have been underscored by the ongoing KONFIDENT phase 3 clinical trial, which is the largest ever conducted for HAE. These developments highlight KalVista’s strategic focus on addressing unmet needs in the HAE treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.